Aripiprazole
Indication
Treatment of Schizophrenia in adults. Treatment of Schizophrenia in people aged 15 to 17 years (NICE TA213)
NICE TA213 - Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.
Amber level 1
Brand:
Abilify®
Nice TA:
213
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Central nervous system
Background
Recommended for the Treatment of Schizophrenia in adults by LSCMMG in line with Lancashire Care Foundation Trust Formulary.
Recommended for the Treatment of Schizophrenia in people aged 15 to 17 years in line with NICE TA 213.
Recommendation
LSCMMG Recommendation:
Amber level 1
Reason for decision:
Shared care required
Supporting documents: